Skip to main content

HPV 16 Infection

2
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
2100%
+ 1 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

MSD
MSDIreland - Ballydine
1 program
1
Comparator: HPV 16 L1 VaccinePhase 2Vaccine1 trial
Active Trials
NCT00365378Completed2,409Est. Jul 2009
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
Comparator: HPV 16 L1 VaccinePhase 2Vaccine
Papivax
PapivaxTaiwan - Taipei
1 program
pNGVL4a-Sig/E7PHASE_11 trial
Active Trials
NCT06508138Enrolling By Invitation24Est. Oct 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
MSDComparator: HPV 16 L1 Vaccine
PapivaxpNGVL4a-Sig/E7

Clinical Trials (2)

Total enrollment: 2,433 patients across 2 trials

NCT00365378MSDComparator: HPV 16 L1 Vaccine

Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)

Start: Sep 1999Est. completion: Jul 20092,409 patients
Phase 2Completed
NCT06508138PapivaxpNGVL4a-Sig/E7

Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood Collection

Start: Oct 2023Est. completion: Oct 202724 patients
Phase 1Enrolling By Invitation

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

Vaccine is the dominant modality (100% of programs)
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.